A prospective targeted serum metabolomics study of pancreatic cancer in postmenopausal women

Abstract

To examine the association between metabolic dereg-q-value < 0.25 was indicated statistically significant. ulation and pancreatic cancer, we conducted a two-stage Logistic regression model and ROC curve analysis were case–control targeted metabolomics study using pre-used to evaluate the clinical utility of the metabolites. diagnostic sera collected one year before diagnosis in the Among 30 case/control pairs, 1-methyl-L-tryptophan Women's Health Initiative study. We used the LC/MS to (L-1MT) was significantly lower in the cases than in the quantitate 470 metabolites in 30 matched case/control controls (log 2 FC ¼ 0.35; q-value ¼ 0.03). The area pairs. From 180 detectable metabolites, we selected 14 under the ROC curve was 0.83 in the discrimination metabolites to be validated in additional 18 matched analysis based on the levels of L-1MT, acadesine, and case/control pairs. We used the paired t test to compare aspartic acid. None of the metabolites was validated in the concentrations of each metabolite between cases additional independent 18 case/control pairs. No sig- and controls and used the log fold change (FC) to nificant association was found between the examined indicate the magnitude of difference. FDR adjusted metabolites and undiagnosed pancreatic cancer.